Combination Elotuzumab and Lenalidomide Treatment Efficacy Is Dependent on Crosstalk between NK Cells, Monocytes and Myeloma Cells

Researchers used a humanized myeloma mouse model and adoptive transfer of human NK cells to show that elotuzumab and lenalidomide treatment controlled myeloma growth, and this was mediated through CD16 on NK cells.